Evidence map›Paper›PMID 32603516›Full record

Observational studyThe Laryngoscope2021

Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients.

Jose F Polanski, Eloise A Tanaka, Harymy Barros, Adriana G Chuchene, Patricia T G Miguel, Thelma L Skare

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Laryngoscope, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jose F PolanskiDepartment of Otorhinolaryngology-Head and Neck Surgery, Federal University of Parana, and Mackenzie Evangelical School of Medicine-Parana, Curitiba, Brazil.ORCID 0000-0003-3151-2327
Eloise A TanakaRheumatology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine -Parana, Curitiba, Brazil.
Harymy BarrosRheumatology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine -Parana, Curitiba, Brazil.
Adriana G ChucheneAudiology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine-Parana, Curitiba, Brazil.
Patricia T G MiguelAudiology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine-Parana, Curitiba, Brazil.
Thelma L SkareRheumatology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine -Parana, Curitiba, Brazil.
Hospital Universitário Evangélico de Curitiba · BRUniversidade Federal do Paraná · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectives/hypothesisAntimalarial drugs (chloroquine and hydroxychloroquine) are widely used for the treatment of systemic lupus erythematosus (SLE). However, these drugs may have side effects such as hearing loss. This study aimed to describe the hearing function in SLE patients using antimalarials. Secondarily, this study aimed to investigate whether SLE causes hearing loss and if there are any serological or clinical aspects of this diseases associated with inner ear damage. STUDY

designCross-sectional study.

methodsThis study included 84 individuals (43 SLE patients and 41 controls) with audiometry and tympanometry tests. Epidemiological, clinical, serological, and treatment profiles of SLE patients were extracted from the charts.

resultsSLE patients had more sensorineural hearing loss than controls (23.2% vs. 0; P = .001). Pure-tone averages in SLE patients using antimalarials and not using antimalarials were similar (8.75 vs. 8.75; P = .63). At 8,000 Hz, antimalarial dug nonusers performed worse than users (10.00 vs. 22.50; P = .03). Tympanometry was normal in all participants. SLE serological and clinical profiles in patients with and without hearing loss were the same (all P = nonsignificant).

conclusionsThere is a high prevalence of hearing loss in SLE that is not affected by antimalarial drug use. LEVEL OF EVIDENCE: 3b Laryngoscope, 131:E957-E960, 2021.

Indexed as

Acoustic Impedance TestsAdultAntimalarialsAudiometry, Pure-ToneChloroquineCross-Sectional StudiesFemaleHearing Loss, SensorineuralHumansHydroxychloroquineLupus Erythematosus, SystemicMaleMiddle AgedPrevalenceAntimalarialsChloroquineHydroxychloroquineantimalarialsChloroquinehearing lossinner earsystemic lupus erythematosus

Identifiers

PMID32603516
PMCPMC7361380
OpenAlexW3038662826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.